FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120350411> ?p ?o ?g. }

• W2120350411 endingPage "2658" @default.
• W2120350411 startingPage "2644" @default.
• W2120350411 abstract "The cyclin-dependent protein kinases are key regulators of cell cycle progression. Aberrant expression or altered activity of distinct cyclin-dependent kinase (CDK) complexes results in escape of cells from cell cycle control, leading to unrestricted cell proliferation. CDK inhibitors have the potential to induce cell cycle arrest and apoptosis in cancer cells, and identifying small-molecule CDK inhibitors has been a major focus in cancer research. Several CDK inhibitors are entering the clinic, the most recent being selective CDK2 and CDK4 inhibitors. We have identified a diaminopyrimidine compound, R547, which is a potent and selective ATP-competitive CDK inhibitor. In cell-free assays, R547 effectively inhibited CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1 (K(i) = 1-3 nmol/L) and was inactive (K(i) > 5,000 nmol/L) against a panel of >120 unrelated kinases. In vitro, R547 effectively inhibited the proliferation of tumor cell lines independent of multidrug resistant status, histologic type, retinoblastoma protein, or p53 status, with IC(50)s </= 0.60 mumol/L. The growth-inhibitory activity is characterized by a cell cycle block at G(1) and G(2) phases and induction of apoptosis. R547 reduced phosphorylation of the cellular retinoblastoma protein at specific CDK phosphorylation sites at the same concentrations that induced cell cycle arrest, suggesting a potential pharmacodynamic marker for clinical use. In vivo, R547 showed antitumor activity in all of the models tested to date, including six human tumor xenografts and an orthotopic syngeneic rat model. R547 was efficacious with daily oral dosing as well as with once weekly i.v. dosing in established human tumor models and at the targeted efficacious exposures inhibited phosphorylation of the retinoblastoma protein in the tumors. The selective kinase inhibition profile and the preclinical antitumor activity of R547 suggest that it may be promising for development for use in the treatment of solid tumors. R547 is currently being evaluated in phase I clinical trials." @default.
• W2120350411 created "2016-06-24" @default.
• W2120350411 creator A5002481596 @default.
• W2120350411 creator A5005659795 @default.
• W2120350411 creator A5007041344 @default.
• W2120350411 creator A5012238055 @default.
• W2120350411 creator A5014901839 @default.
• W2120350411 creator A5025596555 @default.
• W2120350411 creator A5030748431 @default.
• W2120350411 creator A5036340684 @default.
• W2120350411 creator A5037197542 @default.
• W2120350411 creator A5041091045 @default.
• W2120350411 creator A5050039619 @default.
• W2120350411 creator A5055435856 @default.
• W2120350411 creator A5059358713 @default.
• W2120350411 creator A5066696385 @default.
• W2120350411 creator A5068633398 @default.
• W2120350411 creator A5071297737 @default.
• W2120350411 creator A5072303662 @default.
• W2120350411 creator A5073724198 @default.
• W2120350411 creator A5078714909 @default.
• W2120350411 creator A5084861371 @default.
• W2120350411 date "2006-11-01" @default.
• W2120350411 modified "2023-10-14" @default.
• W2120350411 title "<i>In vitro</i> and <i>in vivo</i> activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials" @default.
• W2120350411 cites W1629179716 @default.
• W2120350411 cites W1795737833 @default.
• W2120350411 cites W1973586213 @default.
• W2120350411 cites W1990750564 @default.
• W2120350411 cites W1991054314 @default.
• W2120350411 cites W1992509138 @default.
• W2120350411 cites W1995670756 @default.
• W2120350411 cites W2010991568 @default.
• W2120350411 cites W2015008270 @default.
• W2120350411 cites W2015404852 @default.
• W2120350411 cites W2018528698 @default.
• W2120350411 cites W2025618547 @default.
• W2120350411 cites W2029080338 @default.
• W2120350411 cites W2030545569 @default.
• W2120350411 cites W2039771541 @default.
• W2120350411 cites W2058891255 @default.
• W2120350411 cites W2064076258 @default.
• W2120350411 cites W2076009547 @default.
• W2120350411 cites W2078122867 @default.
• W2120350411 cites W2080443370 @default.
• W2120350411 cites W2081970496 @default.
• W2120350411 cites W2084810833 @default.
• W2120350411 cites W2088355640 @default.
• W2120350411 cites W2089167153 @default.
• W2120350411 cites W2091298934 @default.
• W2120350411 cites W2098203835 @default.
• W2120350411 cites W2104373322 @default.
• W2120350411 cites W2109521827 @default.
• W2120350411 cites W2113604152 @default.
• W2120350411 cites W2121543046 @default.
• W2120350411 cites W2121594851 @default.
• W2120350411 cites W2128956884 @default.
• W2120350411 cites W2129496457 @default.
• W2120350411 cites W2129581056 @default.
• W2120350411 cites W2144002245 @default.
• W2120350411 cites W2148180201 @default.
• W2120350411 cites W2153451248 @default.
• W2120350411 cites W2154626333 @default.
• W2120350411 cites W2162517036 @default.
• W2120350411 cites W2177166422 @default.
• W2120350411 cites W4245211736 @default.
• W2120350411 doi "https://doi.org/10.1158/1535-7163.mct-06-0355" @default.
• W2120350411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17121911" @default.
• W2120350411 hasPublicationYear "2006" @default.
• W2120350411 type Work @default.
• W2120350411 sameAs 2120350411 @default.
• W2120350411 citedByCount "94" @default.
• W2120350411 countsByYear W21203504112012 @default.
• W2120350411 countsByYear W21203504112013 @default.
• W2120350411 countsByYear W21203504112014 @default.
• W2120350411 countsByYear W21203504112015 @default.
• W2120350411 countsByYear W21203504112016 @default.
• W2120350411 countsByYear W21203504112017 @default.
• W2120350411 countsByYear W21203504112018 @default.
• W2120350411 countsByYear W21203504112019 @default.
• W2120350411 countsByYear W21203504112020 @default.
• W2120350411 countsByYear W21203504112021 @default.
• W2120350411 countsByYear W21203504112022 @default.
• W2120350411 countsByYear W21203504112023 @default.
• W2120350411 crossrefType "journal-article" @default.
• W2120350411 hasAuthorship W2120350411A5002481596 @default.
• W2120350411 hasAuthorship W2120350411A5005659795 @default.
• W2120350411 hasAuthorship W2120350411A5007041344 @default.
• W2120350411 hasAuthorship W2120350411A5012238055 @default.
• W2120350411 hasAuthorship W2120350411A5014901839 @default.
• W2120350411 hasAuthorship W2120350411A5025596555 @default.
• W2120350411 hasAuthorship W2120350411A5030748431 @default.
• W2120350411 hasAuthorship W2120350411A5036340684 @default.
• W2120350411 hasAuthorship W2120350411A5037197542 @default.
• W2120350411 hasAuthorship W2120350411A5041091045 @default.
• W2120350411 hasAuthorship W2120350411A5050039619 @default.
• W2120350411 hasAuthorship W2120350411A5055435856 @default.
• W2120350411 hasAuthorship W2120350411A5059358713 @default.

• next